Matinas BioPharma Investor Presentation Deck

20 Unlocking the Full Potential of the LNC Platform Matinas is working internally and with third parties to broaden its pipeline of LNC-based therapeutics PROVEN Oral Formulations of Anti-Infectives ● MAT2203 Remdesivir MAT2501 Oral Formulations of Chemotherapeutics Docetaxel UNDER EVALUATION Intracellular Delivery of Nucleic Acids siRNA ASO FUTURE Potential Therapeutic Applications INFECTION COPYRIGHT MATINAS BIOPHARMA ● *INFLAMMATION Autoimmune diseases ● Anti-infectives Antivirals • Neuro-inflammatory ● diseases Acute/chronic Inflammatory diseases *ONCOLOGY • Hematologic & solid tumor malignancies * Key Areas of Focus for Internal LNC Oral Small Oligonucleotides 2024 MATINAS BIOPHARMA

View entire presentation